Lung Kee (Bermuda) Holdings Limited Logo

Lung Kee (Bermuda) Holdings Limited

0255.HK

(2.2)
Stock Price

1,14 HKD

0.69% ROA

-2.96% ROE

54.72x PER

Market Cap.

865.397.490,00 HKD

0.48% DER

11.68% Yield

-4.04% NPM

Lung Kee (Bermuda) Holdings Limited Stock Analysis

Lung Kee (Bermuda) Holdings Limited Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Lung Kee (Bermuda) Holdings Limited Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.47x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Dividend

The company's consistent dividend distribution over the past five years reflects its dedication to providing shareholders with steady returns, making it an appealing choice for investors seeking income stability.

4 ROE

ROE in an average range (0.74%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 ROA

The stock's ROA (0.69%) shows that it's doing a pretty good job at making money from its assets, making it a solid choice to invest and earn steady profits.

6 Buffet Intrinsic Value

The company's stock seems undervalued (132) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

7 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

9 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

10 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

11 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

Lung Kee (Bermuda) Holdings Limited Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Lung Kee (Bermuda) Holdings Limited Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Hold
4 Stoch RSI Hold

Lung Kee (Bermuda) Holdings Limited Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Lung Kee (Bermuda) Holdings Limited Revenue
Year Revenue Growth
1996 583.098.412
1997 663.681.098 12.14%
1998 686.126.737 3.27%
1999 686.126.737 0%
2000 889.542.358 22.87%
2001 985.833.563 9.77%
2002 801.393.000 -23.01%
2003 1.209.613.000 33.75%
2004 1.599.505.000 24.38%
2005 1.899.482.000 15.79%
2006 2.135.360.000 11.05%
2007 2.702.099.000 20.97%
2008 3.073.547.000 12.09%
2009 2.234.680.000 -37.54%
2010 2.611.583.000 14.43%
2011 2.532.460.000 -3.12%
2012 2.401.503.000 -5.45%
2013 2.221.203.000 -8.12%
2014 2.403.429.000 7.58%
2015 2.279.124.000 -5.45%
2016 2.213.126.000 -2.98%
2017 2.510.389.000 11.84%
2018 2.580.453.000 2.72%
2019 2.277.883.000 -13.28%
2019 2.277.883.000 0%
2020 2.064.882.000 -10.32%
2021 2.273.399.000 9.17%
2022 1.601.433.000 -41.96%
2023 1.449.340.000 -10.49%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Lung Kee (Bermuda) Holdings Limited Research and Development Expenses
Year Research and Development Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Lung Kee (Bermuda) Holdings Limited General and Administrative Expenses
Year General and Administrative Expenses Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 11.099.000 100%
2021 11.382.000 2.49%
2022 11.101.000 -2.53%
2023 4.219.000 -163.12%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Lung Kee (Bermuda) Holdings Limited EBITDA
Year EBITDA Growth
1996 583.098.412
1997 663.681.098 12.14%
1998 686.126.737 3.27%
1999 165.885.812 -313.61%
2000 242.332.726 31.55%
2001 264.237.633 8.29%
2002 211.056.000 -25.2%
2003 319.462.000 33.93%
2004 314.921.000 -1.44%
2005 678.507.000 53.59%
2006 276.435.000 -145.45%
2007 549.917.000 49.73%
2008 648.868.000 15.25%
2009 509.004.000 -27.48%
2010 626.829.000 18.8%
2011 550.679.000 -13.83%
2012 438.781.000 -25.5%
2013 769.476.000 42.98%
2014 784.993.000 1.98%
2015 797.040.000 1.51%
2016 890.392.000 10.48%
2017 469.055.000 -89.83%
2018 391.996.000 -19.66%
2019 366.100.000 -7.07%
2019 327.070.000 -11.93%
2020 336.184.000 2.71%
2021 445.304.000 24.5%
2022 162.578.000 -173.9%
2023 39.546.000 -311.11%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Lung Kee (Bermuda) Holdings Limited Gross Profit
Year Gross Profit Growth
1996 583.098.412
1997 663.681.098 12.14%
1998 686.126.737 3.27%
1999 407.916.113 -68.2%
2000 460.261.570 11.37%
2001 518.324.104 11.2%
2002 444.418.000 -16.63%
2003 688.307.000 35.43%
2004 814.240.000 15.47%
2005 997.361.000 18.36%
2006 1.007.233.000 0.98%
2007 1.412.476.000 28.69%
2008 1.612.042.000 12.38%
2009 1.206.185.000 -33.65%
2010 1.513.254.000 20.29%
2011 1.412.723.000 -7.12%
2012 1.315.477.000 -7.39%
2013 1.279.189.000 -2.84%
2014 1.361.234.001 6.03%
2015 1.369.636.000 0.61%
2016 1.440.566.000 4.92%
2017 1.507.005.000 4.41%
2018 1.496.760.000 -0.68%
2019 1.388.216.000 -7.82%
2019 690.997.000 -100.9%
2020 653.190.000 -5.79%
2021 777.066.000 15.94%
2022 397.999.000 -95.24%
2023 263.905.000 -50.81%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Lung Kee (Bermuda) Holdings Limited Net Profit
Year Net Profit Growth
1996 210.621.190
1997 103.478.810 -103.54%
1998 66.368.855 -55.91%
1999 83.011.812 20.05%
2000 142.114.298 41.59%
2001 162.068.816 12.31%
2002 93.360.000 -73.6%
2003 157.255.000 40.63%
2004 224.990.000 30.11%
2005 245.917.000 8.51%
2006 151.068.000 -62.79%
2007 307.500.000 50.87%
2008 288.333.000 -6.65%
2009 220.928.000 -30.51%
2010 318.825.000 30.71%
2011 273.965.000 -16.37%
2012 196.529.000 -39.4%
2013 145.197.000 -35.35%
2014 137.837.000 -5.34%
2015 125.632.000 -9.71%
2016 191.731.000 34.47%
2017 278.276.000 31.1%
2018 170.521.000 -63.19%
2019 149.339.000 -14.18%
2019 149.339.000 0%
2020 181.081.000 17.53%
2021 227.841.000 20.52%
2022 15.814.000 -1340.76%
2023 -72.431.000 121.83%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Lung Kee (Bermuda) Holdings Limited Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1996 0
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 1 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Lung Kee (Bermuda) Holdings Limited Free Cashflow
Year Free Cashflow Growth
1996 52.551.873
1997 83.185.646 36.83%
1998 139.545.325 40.39%
1999 139.545.325 0%
2000 109.437.424 -27.51%
2001 143.806.690 23.9%
2002 151.869.000 5.31%
2003 -40.930.000 471.05%
2004 77.054.000 153.12%
2005 17.807.000 -332.72%
2006 -111.873.000 115.92%
2007 255.949.000 143.71%
2008 602.226.000 57.5%
2009 590.342.000 -2.01%
2010 145.444.000 -305.89%
2011 -32.308.000 550.18%
2012 237.940.000 113.58%
2013 36.411.000 -553.48%
2014 -105.716.000 134.44%
2015 270.292.000 139.11%
2016 373.513.000 27.64%
2017 104.894.000 -256.09%
2018 236.826.000 55.71%
2019 62.416.000 -279.43%
2020 241.638.000 74.17%
2021 152.416.000 -58.54%
2022 -105.475.000 244.5%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Lung Kee (Bermuda) Holdings Limited Operating Cashflow
Year Operating Cashflow Growth
1996 129.129.079
1997 209.628.897 38.4%
1998 222.174.849 5.65%
1999 222.174.849 0%
2000 203.190.016 -9.34%
2001 263.297.182 22.83%
2002 226.112.000 -16.45%
2003 90.348.000 -150.27%
2004 262.819.000 65.62%
2005 304.829.000 13.78%
2006 158.159.000 -92.74%
2007 348.471.000 54.61%
2008 829.233.000 57.98%
2009 657.954.000 -26.03%
2010 324.034.000 -103.05%
2011 522.301.000 37.96%
2012 524.721.000 0.46%
2013 249.360.000 -110.43%
2014 157.503.000 -58.32%
2015 372.872.000 57.76%
2016 485.135.000 23.14%
2017 231.368.000 -109.68%
2018 323.161.000 28.4%
2019 83.089.750 -288.93%
2020 354.686.000 76.57%
2021 353.745.000 -0.27%
2022 76.865.000 -360.22%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Lung Kee (Bermuda) Holdings Limited Capital Expenditure
Year Capital Expenditure Growth
1996 76.577.206
1997 126.443.251 39.44%
1998 82.629.524 -53.02%
1999 82.629.524 0%
2000 93.752.592 11.86%
2001 119.490.492 21.54%
2002 74.243.000 -60.95%
2003 131.278.000 43.45%
2004 185.765.000 29.33%
2005 287.022.000 35.28%
2006 270.032.000 -6.29%
2007 92.522.000 -191.86%
2008 227.007.000 59.24%
2009 67.612.000 -235.75%
2010 178.590.000 62.14%
2011 554.609.000 67.8%
2012 286.781.000 -93.39%
2013 212.949.000 -34.67%
2014 263.219.000 19.1%
2015 102.580.000 -156.6%
2016 111.622.000 8.1%
2017 126.474.000 11.74%
2018 86.335.000 -46.49%
2019 20.673.750 -317.61%
2020 113.048.000 81.71%
2021 201.329.000 43.85%
2022 182.340.000 -10.41%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Lung Kee (Bermuda) Holdings Limited Equity
Year Equity Growth
1996 458.479.976
1997 507.359.403 9.63%
1999 534.337.420 5.05%
2000 584.230.263 8.54%
2001 642.232.681 9.03%
2002 750.034.000 14.37%
2003 853.983.000 12.17%
2004 991.541.000 13.87%
2005 1.136.497.000 12.75%
2006 1.244.351.000 8.67%
2007 1.584.097.000 21.45%
2008 1.818.267.000 12.88%
2009 1.928.478.000 5.71%
2010 2.176.403.000 11.39%
2011 2.308.130.000 5.71%
2012 2.413.074.000 4.35%
2013 2.477.816.000 2.61%
2014 2.369.960.000 -4.55%
2015 2.282.235.000 -3.84%
2016 2.206.758.000 -3.42%
2017 2.342.157.000 5.78%
2018 2.166.831.000 -8.09%
2019 2.115.070.000 -2.45%
2020 2.274.394.000 7.01%
2021 2.271.272.000 -0.14%
2022 1.986.581.000 -14.33%
2023 1.847.349.000 -7.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Lung Kee (Bermuda) Holdings Limited Assets
Year Assets Growth
1996 578.764.285
1997 792.132.551 26.94%
1999 878.132.973 9.79%
2000 1.134.981.657 22.63%
2001 1.413.084.393 19.68%
2002 1.749.161.000 19.21%
2003 1.830.757.000 4.46%
2004 1.997.743.000 8.36%
2005 2.006.002.000 0.41%
2006 2.310.684.000 13.19%
2007 2.713.387.000 14.84%
2008 2.478.759.000 -9.47%
2009 2.375.160.000 -4.36%
2010 2.967.230.000 19.95%
2011 3.120.942.000 4.93%
2012 3.095.740.000 -0.81%
2013 3.209.787.000 3.55%
2014 3.007.420.000 -6.73%
2015 2.779.313.000 -8.21%
2016 2.733.392.000 -1.68%
2017 2.851.808.000 4.15%
2018 2.630.087.000 -8.43%
2019 2.570.494.000 -2.32%
2020 2.745.644.000 6.38%
2021 2.745.732.000 0%
2022 2.301.477.000 -19.3%
2023 2.136.068.000 -7.74%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Lung Kee (Bermuda) Holdings Limited Liabilities
Year Liabilities Growth
1996 9.779.803
1997 157.719.805 93.8%
1999 207.407.944 23.96%
2000 386.975.169 46.4%
2001 592.566.998 34.7%
2002 978.419.000 39.44%
2003 965.005.000 -1.39%
2004 985.340.000 2.06%
2005 845.048.000 -16.6%
2006 1.063.730.000 20.56%
2007 1.128.360.000 5.73%
2008 655.636.000 -72.1%
2009 441.692.000 -48.44%
2010 781.862.000 43.51%
2011 804.310.000 2.79%
2012 671.508.000 -19.78%
2013 719.484.000 6.67%
2014 624.011.000 -15.3%
2015 482.844.000 -29.24%
2016 511.271.000 5.56%
2017 509.651.000 -0.32%
2018 463.256.000 -10.01%
2019 455.424.000 -1.72%
2020 471.250.000 3.36%
2021 474.460.000 0.68%
2022 314.896.000 -50.67%
2023 288.719.000 -9.07%

Lung Kee (Bermuda) Holdings Limited Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
2.54
Net Income per Share
0.03
Price to Earning Ratio
54.72x
Price To Sales Ratio
0.54x
POCF Ratio
11.26
PFCF Ratio
-8.2
Price to Book Ratio
0.44
EV to Sales
0.21
EV Over EBITDA
2.04
EV to Operating CashFlow
4.4
EV to FreeCashFlow
-3.21
Earnings Yield
0.02
FreeCashFlow Yield
-0.12
Market Cap
0,87 Bil.
Enterprise Value
0,34 Bil.
Graham Number
1.33
Graham NetNet
0.83

Income Statement Metrics

Net Income per Share
0.03
Income Quality
3.55
ROE
0.01
Return On Assets
-0.03
Return On Capital Employed
-0.05
Net Income per EBT
0.68
EBT Per Ebit
0.83
Ebit per Revenue
-0.07
Effective Tax Rate
0.32

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.18
Operating Profit Margin
-0.07
Pretax Profit Margin
-0.06
Net Profit Margin
-0.04

Dividends

Dividend Yield
0.12
Dividend Yield %
11.68
Payout Ratio
10.38
Dividend Per Share
0.16

Operating Metrics

Operating Cashflow per Share
0.12
Free CashFlow per Share
-0.17
Capex to Operating CashFlow
-2.37
Capex to Revenue
-0.11
Capex to Depreciation
-1.15
Return on Invested Capital
0
Return on Tangible Assets
0.01
Days Sales Outstanding
0
Days Payables Outstanding
77.64
Days of Inventory on Hand
346.96
Receivables Turnover
0
Payables Turnover
4.7
Inventory Turnover
1.05
Capex per Share
-0.29

Balance Sheet

Cash per Share
0,85
Book Value per Share
3,14
Tangible Book Value per Share
3.14
Shareholders Equity per Share
3.14
Interest Debt per Share
0.02
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-3.19
Current Ratio
6.55
Tangible Asset Value
1,99 Bil.
Net Current Asset Value
0,98 Bil.
Invested Capital
0
Working Capital
1,10 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,19 Bil.
Average Inventory
605599500
Debt to Market Cap
0.01

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Lung Kee (Bermuda) Holdings Limited Dividends
Year Dividends Growth
2000 0
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Lung Kee (Bermuda) Holdings Limited Profile

About Lung Kee (Bermuda) Holdings Limited

Lung Kee (Bermuda) Holdings Limited, an investment holding company, manufactures and markets mold bases and related products in the People's Republic of China and internationally. The company was founded in 1975 and is headquartered in Sha Tin, Hong Kong. Lung Kee (Bermuda) Holdings Limited is a subsidiary of Pan Island Investments Limited.

CEO
Mr. Tit Lung Siu
Employee
2.900
Address
Unit A, Kings Wing Plaza 2
Sha Tin,

Lung Kee (Bermuda) Holdings Limited Executives & BODs

Lung Kee (Bermuda) Holdings Limited Executives & BODs
# Name Age
1 Mr. Lung Shing Wai FCCA, FHKSA
Company Secretary & Executive Director
70
2 Mr. Tit Lung Siu
Co-Founder & Executive Chairman
70
3 Mr. Yuk Lung Siu
Co-Founder, MD & Executive Director
70
4 Mr. Chung Ho Ting
Executive Director
70
5 Mr. Yuk Tung Siu
Executive Director
70
6 Mr. Yu Hang Siu
Executive Director
70

Lung Kee (Bermuda) Holdings Limited Competitors